E-mail: lling@51chemall.com
Contact Us
Wuhan Lihe New Chemical Materials Co.,Ltd
Tel:+86-027-88395717
Mob:+8613007129042
Fax:+86-027-88391805
E-mail:lling@51chemall.com
Add: Room 1801, Building B, Wuhan University Of Technology Entrepreneur Incubator, Hongshan, Wuhan, Hubei, China
Home > News > Content
Treatment Of Constipation-type Irritable Bowel Syndrome New Drug Linaclotide Officially Approved In China
Jan 16, 2019

Linaclotide has been approved for marketing in more than 30 countries around the world for the treatment of constipation-type irritable bowel syndrome. AstraZeneca and Ironwood Pharmaceutical Co., Ltd. reached a cooperation in 2012, jointly responsible for the development and listing of Zeshu in China.

 

It is understood that constipation-type irritable bowel syndrome (IBS-C) is a recurrent episode, which is the main feature of functional bowel disease with abdominal pain, bloating and abdominal discomfort, which seriously affects the quality of work and life. Ze Zeshu's innovative mechanism is to activate the body's own guanylate cyclase to promote intestinal secretion, and to reduce the visceral hypersensitivity, to relieve abdominal pain, bloating and constipation in patients with constipation-type irritable bowel syndrome. The effect of the symptoms.

 

Professor Chen Yihu, the chairman of the Chinese Medical Association Digestive Diseases Branch and the vice president of the First Affiliated Hospital of Sun Yat-sen University, said: "Constipation-type irritable bowel syndrome is a disease that affects the quality of life. The current treatment is very limited. Linalo. The peptide has been approved for marketing, providing a new choice for the treatment of patients with irritable bowel syndrome, and will also promote the standardization and standardization of constipation-type irritable bowel syndrome, and improve the diagnosis and treatment of constipation-type irritable bowel syndrome in China. Significance."

 

Professor Tang Chengwei, the deputy director of the Chinese Medical Association Digestive Diseases Branch and director of the Department of Gastroenterology, West China Hospital of Sichuan University, said: "Linaglutide is the first guanylate cyclase agonist approved in mainland China. The listing will provide better treatment options for patients with constipation-type irritable bowel syndrome in China, and help patients improve their symptoms and improve their quality of life from a new perspective."

 

Chen Zhijian, senior vice president of global drug development at AstraZeneca and president of China New Drug Development Department, said: "AstraZeneca China New Drug Development Department has always been 'patient-centered' and is committed to discovering and meeting the most pressing treatment needs of Chinese patients. The approval will bring groundbreaking treatments for patients with constipation-type irritable bowel syndrome in China."

 

"As an innovative prescription drug for the treatment of constipation-type irritable bowel syndrome, Zeshu has filled the treatment gap in China." Alibaba's global executive vice president, international business and China president Wang Lei said: "In the future, AstraZeneca still It is our responsibility to introduce global innovative drugs into China. At the same time, we work together with professional associations, physicians and partners in the field of digestive fields to improve the accessibility of drugs and enable Chinese patients to enjoy the treatment of new international drugs in the first place."


Copyright © Wuhan Lihe New Chemical Materials Co.,Ltd All Rights Reserved.